FMP
Lumos Pharma, Inc.
LUMO
NASDAQ
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
2.81 USD
-0.01 (-0.356%)
About
ceo
Mr. Richard J. Hawkins
sector
Healthcare
industry
Biotechnology
website
https://www.lumos-pharma.com
exchange
NASDAQ
Description
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
CIK
0001126234
ISIN
US55028X1090
CUSIP
55028X109
Address
4200 Marathon Boulevard
Phone
512 215 2630
Country
US
Employee
33
IPO Date
Nov 11, 2011
Summary
CIK
0001126234
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
55028X109
ISIN
US55028X1090
Country
US
Price
2.81
Beta
0.35
Volume Avg.
20.28k
Market Cap
22.78M
Shares
-
52-Week
2.41-4.55
DCF
-0.01
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.67
P/B
-
Website
https://www.lumos-pharma.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest LUMO News
It looks like there's no news available.
